[
    "\"EMI-C00031\" path=\"US08937193-20150120-C00031.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598822/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00031.TIF\"/>+++0.59 \u00b1 0.220.13 \u00b1 0.080.31 \u00b1 0.1910.1 \u00b1 0.046.9 \u00b1 1.76 6j<img id=\"EMI-C00032\" path=\"US08937193-20150120-C00032.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598873/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00032.TIF\"/>+8.99 \u00b1 2.491.44 \u00b1 0.202.38 \u00b1 0.2116.12 \u00b1 0.077.32 \u00b1 0.90 6k<img id=\"EMI-C00033\" path=\"US08937193-20150120-C00033.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598792/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00033.TIF\"/>+2.62 \u00b1 0.311.48 \u00b1 0.021.91 \u00b1 0.1714.61 \u00b1 0.0611.25 \u00b1 0.54 6l<img id=\"EMI-C00034\" path=\"US08937193-20150120-C00034.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598824/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00034.TIF\"/>+++0.21 \u00b1 0.050.19 \u00b1 0.042.99 \u00b1 1.210.48 \u00b1 0.011.13 \u00b1 0.60 6m<img id=\"EMI-C00035\" path=\"US08937193-20150120-C00035.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598741/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00035.TIF\"/>+++2.97 \u00b1 0.980.98 \u00b1 0.1510.30 \u00b1 3.840.81 \u00b1 0.061.74 \u00b1 0.11<sup>a*</sup>4-point-rating scale: +++: Very Active; ++: Active; +: Mild; \u2212: Weak<sup>b*</sup>Compounds against cell line using ATP-LITE assay<sup>c*</sup>Compounds against cell line using Annexin V-FITC and propidium iodide assay</p>To confirm the results from the 1D <sup>1</sup>H NMR binding assay described above, <sup>15</sup>N-labeled Bcl-X<sub>L </sub>protein was produced and measured by 2D [<sup>15</sup>N, <sup>1</sup>H]-HSQC correlation spectra in absence and presence of selected compounds. Consistent with 1D <sup>1</sup>H NMR binding assays, compounds 6f, 6i and 8a displayed strong binding to Bcl-X<sub>L</sub>, as qualitatively evaluated by the nature of the shifts at the ligand/protein ratio of 1:1. To confirm the results of the NMR binding data, the binding affinity of selected compounds for Bcl-X<sub>L </sub>using FP assay were evaluated. Table 3 demonstrates the cross-activity of selected 5,5\u2032 substituted 6a derivatives against Bcl-X<sub>L</sub>, Bcl-2, Mcl-1 and Bfl-1.</p>TABLE 3IC<sub>50 </sub>(\u03bcM) FPAK<sub>d </sub>(\u03bcM) ITCCompoundBcl-X<sub>L</sub>Bcl-2Bfl-1Mcl-1Bcl-X<sub>L</sub>6a0.63 \u00b1 0.020.37 \u00b1 0.022.17 \u00b1 0.350.54 \u00b1 0.032.80 \u00b1 0.606b0.55 \u00b1 0.060.25 \u00b1 0.021.41 \u00b1 0.110.47 \u00b1 0.031.50 \u00b1 0.806f3.10 \u00b1 0.283.12 \u00b1 0.1514.7 \u00b1 6.632.05 \u00b1 0.152.50 \u00b1 2.206i0.34 \u00b1 0.030.29 \u00b1 0.010.65 \u00b1 0.050.24 \u00b1 0.020.45 \u00b1 0.266c2.99 \u00b1 0.162.27 \u00b1 0.15ND<sup>a</sup>*3.08 \u00b1 0.17ND6d12.65 \u00b1 4.34\u20026.73 \u00b1 2.24ND5.90 \u00b1 0.54ND6e1.79 \u00b1 0.142.57 \u00b1 0.129.72 \u00b1 1.381.29 \u00b1 0.05ND6g1.44 \u00b1 0.062.17 \u00b1 0.145.27 \u00b1 0.760.67 \u00b1 0.03ND6l0.15 \u00b1 0.060.34 \u00b1 0.060.70 \u00b1 0.070.40 \u00b1 0.05ND70.34 \u00b1 0.020.22 \u00b1 0.020.69 \u00b1 0.030.35 \u00b1 0.02ND8a0.32 \u00b1 0.010.23 \u00b1 0.010.71 \u00b1 0.060.47 \u00b1 0.03ND8c0.24 \u00b1 0.020.21 \u00b1 0.011.25 \u00b1 0.090.32 \u00b1 0.02NDND<sup>a</sup>* = Not determined</p>In agreement with NMR binding, co",
    "ls are cultured with various concentrations of a compound of Formula I for 1-2 days. The percentage of viable cells may be determined by FITC-Annexin V- and propidium iodide (PI)-labeling, using an Apoptosis Detection kit (BioVision Inc.), and analyzing stained cells by flow cytometry (FACSort; Bectin-Dickinson, Inc.; Mountain View, Calif.). Cells that are annexin-V-negative and PI-negative are considered viable.</p>The apoptotic activity of the compounds of Formula I against mouse embryonic fibroblast wild-type cells (MEF/WT) and mouse embryonic fibroblast BAX/Bak double knockout cells (MEF/DKO) may be assessed by staining with Annexin V and propidium iodide (PI). MEF/WT and MEF/DKO cells are seeded in 24-well plate at a seeding density of half a million per well (in 1 ml of DMEM medium supplemented by 10% FCS). The next day, a compound of Formula I may be added to wild-type and DKO cells at final concentration of 0, 2.5, 5.0, 7.5 and 10 \u03bcM. On the following day, floating cells are pooled with adherent cells harvested after brief incubation with 0.25% Trypsin/EDTA solution (Gibco/In-Vitrogen Inc.). Cells are centrifuged and supernatant is discarded, and the cell pellet is re-suspended with 0.2 ml of Annexin-V binding buffer, followed by addition of 1 \u03bcl Annexin-FITC and 1 \u03bcl PI (propidium iodide). The percentage of viable cells may be determined by a 3-color FACSort instrument and data analyzed by Flow-Jo program, scoring Annexin V-negative, PI-negative as viable cells. The EC50 values for the compounds of Formula I are provided below in Table 5.</p>TABLE 5<img id=\"EMI-C00041\" path=\"US08937193-20150120-C00041.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598693/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00041.TIF\"/>EC<sub>50 </sub>(\u03bcM)RS4;11H460BP3H1299CompoundR =(\u03bcM)(\u03bcM)(\u03bcM)(\u03bcM)BI97C3<img id=\"EMI-C00042\" path=\"US08937193-20150120-C00042.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598764/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00042.TIF\"/>&gt;305.79.1~30 B197C4<img id=\"EMI-C00043\" path=\"US08937193-20150120-C00043.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598770/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00043.TIF\"/>&gt;306.228.4~30 BI97C5<img id=\"EMI-C00044\" path=\"US08937193-20150120-C00044.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598713/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00044.TIF\"/>&gt;304.410.19.1 BI97C6<img id=\"EMI-C00045\" path=\"US08937193-20150120-C00045.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598794/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00045.TIF\"/>&gt;307.46.110 BI97C7<img id=\"EMI-C00046\" path=\"US08937193-20150120-C00046.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598709/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00046.TIF\"/>11.10.7310.810.6 B197C9<img id=\"EMI-C00047\" path=\"US08937193-20150120-C00047.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598846/US/201501",
    "0-C00049.TIF\"/>4.71.07.50.85 BI97D1<img id=\"EMI-C00050\" path=\"US08937193-20150120-C00050.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598739/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00050.TIF\"/>3.10.594.01.56 BI97D4<img id=\"EMI-C00051\" path=\"US08937193-20150120-C00051.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598860/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00051.TIF\"/>3.00.96.01.5 BI79D5<img id=\"EMI-C00052\" path=\"US08937193-20150120-C00052.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598875/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00052.TIF\"/>15.01.630.02.1 B197D6<img id=\"EMI-C00053\" path=\"US08937193-20150120-C00053.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598814/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00053.TIF\"/>ND<sup>a*</sup>NDNDND BI97D7<img id=\"EMI-C00054\" path=\"US08937193-20150120-C00054.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598724/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00054.TIF\"/>NDNDNDND BI97D8<img id=\"EMI-C00055\" path=\"US08937193-20150120-C00055.TIF\" file=\"https://surechembl.org/api/assets/attachment/290598812/US/20150120/B2/000008/93/71/93/US08937193-20150120-C00055.TIF\"/>NDNDNDNDND<sup>a* </sup>= Not determined</p>Example 5Cross-Activity of Selected Compounds of Formula IThe cross-activity of selected compounds of Formula I, against Bcl-X<sub>L</sub>, Bcl-2, Mcl-1 and Bfl-1 using Fluorescence polarization-based competitive binding assay (FPA) is shown below in Table 6.</p>TABLE 6IC<sub>50 </sub>(\u03bcM)CompoundsBcl-X<sub>L</sub>Bcl-2Blf-1Mcl-1BI97C30.320.230.710.47BI97C50.240.211.30.32BI97C60.360.220.690.35BI97C70.550.251.40.47BI97C93.02.3ND<sup>a</sup>*3.1BI97C1012.66.7ND5.9ND<sup>a</sup>* = Not determined</p>Example 6Plasma Stability, Microsomal Stability, and Cell Permeability of Selected Compounds of Formula ITo test the pharmacological properties of selected compounds of Formula I, the in vitro plasma stability, microsomal stability, and cell membrane permeability were determined. The results are shown below in Table 7.</p>TABLE 7Plasma stabilityMicrosomal StabilityCellCompounds(T = 40 mins)(T = 40 mins)PermeabilityBI97C391%71%\u22127.6BI97C798%69%\u22126.1BI97C1074%98%\u22125.6BI97C1181%89%\u22126.8BI97D186%52%\u22125.0BI97D487%88%\u22127.1ND<sup>a</sup>* = Not determined</p>Example 7Characterization of Selected Compounds of Formula I In VivoThe characterization of selected compounds of Formula I in vivo may be determined. As shown in FIG. 21(A) and FIG. 21(B), the dose dependent effects of BI97C10 and BI97C7, respectively, on shrinkage of Bcl-2 transgenic mice spleen at a single intraperitoneal injection dose of 0.06 and 0.12 mmol/kg did not show any toxicity. All shrinkage data are percentage of maximum reduction of mice spleen size. Also shown in FIG. 21(C), are the effects of compound BI97D1 at 0.12 mmol/kg on reduction of spleen weight of seven Bcl-2 transgenic mice treatment with a single intraperitoneal injection. "
]